As of Thursday 2 April 2019, the Vice-President of the Association of the British Pharmaceutical Industry (ABPI) is Hugo Fry.
Hugo Fry is Managing Director of Sanofi UK, the 6th largest pharmaceutical company in the UK. He is also UK General Manager of Sanofi Pasteur, Sanofi’s vaccines business unit, and a member of the Board of Management of the Association of the British Pharmaceutical Industry (ABPI), the trade association for over 120 companies selling prescription medicines. He is currently the Board sponsor for both vaccines and the Prescription Medicines Code of Practice Authority (PMCPA).
Prior to assuming this role, Hugo has held central strategic positions and commercial operational roles, leading vertically integrated teams from Drug Discovery through Clinical Development, Regulatory Affairs, Market Access, Industrial Affairs, Medical Affairs and Commercialisation. Most recently he was the Chief Marketing Officer for Sanofi Pasteur MSD (SPMSD), leading the commercial effort for the European vaccine Joint Venture.
Hugo joined Aventis UK in 2003 as Head of Commercial Excellence. From 2007, Hugo spent four years in Russia leading Sanofi’s Diabetes, Oncology, Cardiovascular, Internal Medicine and Consumer Healthcare businesses, where he was also responsible for the acquisition and set up of an insulin manufacturing facility. Following a strategic acquisition, he was then appointed General Manager of Zentiva Russia, where he was instrumental in maintaining Zentiva as one of the fastest growing companies in Russia while integrating into the Sanofi Group. Hugo then joined the Sanofi Diabetes Leadership Team as Global project Leader for the lixisenatide family, heading R&D, Industrial affairs and commercial operations before assuming his role at SPMSD.
Hugo holds a B.Sc. in Chemistry from the University of Salford and Studied Finance at London Business School.